Sign Up

Ozempic And Wegovy Maker Cuts Outlook In Surprise Move, Picks New CEO

Shares of Novo Nordisk A/S (NYSE:NVO), the Danish pharmaceutical giant renowned for its weight-loss drug Wegovy and diabetes treatment Ozempic, experienced a significant downturn on Tuesday following the company’s decision to trim its 2025 financial outlook.

This marks the second time this year the company has revised its guidance downwards, signaling growing headwinds in key markets. Novo Nordisk now projects 2025 sales growth to be in the range of 8-14% at constant exchange rates, a notable reduction from its earlier forecast of 13-21%.

Similarly, the outlook for operating profit growth has been lowered to 10-16% from the previously anticipated 16-24%. This revised guidance largely stems from a slower-than-expected penetration of its branded GLP-1 treatments, particularly in the United States, a market increasingly impacted by the persistent use of compounded GLP-1 alternatives.

Also Read: Judge Rules Mylan Did Not Infringe Novo Nordisk Patent In Wegovy Generic Case

The company specifically cited lower growth expectations for Wegovy in the U.S. obesity market and for Ozempic in the U.S. GLP-1 diabetes market. Furthermore, Wegovy’s penetration in certain international markets has also fallen short of expectations, attributing to slower market expansion and heightened competition.

In May, Novo Nordisk already lowered its 2025 guidance, reflecting lower-than-planned penetration of branded GLP-1 treatments in the U.S., impacted by compounded GLP-1s.

Despite the expiry of the FDA’s grace period for mass compounding on May ...